These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26692095)

  • 1. Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.
    Węsierska-Gądek J; Mauritz M
    Future Med Chem; 2016 Jan; 8(1):55-72. PubMed ID: 26692095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
    Węsierska-Gądek J; Kramer MP
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
    Akin S; Babacan T; Sarici F; Altundag K
    J BUON; 2014; 19(1):42-6. PubMed ID: 24659641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
    Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
    J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unliganded estrogen receptor alpha inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21(WAF1)).
    Maynadier M; Ramirez JM; Cathiard AM; Platet N; Gras D; Gleizes M; Sheikh MS; Nirde P; Garcia M
    FASEB J; 2008 Mar; 22(3):671-81. PubMed ID: 17911387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
    Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
    Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclins and related kinases in cancer cells.
    Malumbres M
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
    Yenugonda VM; Deb TB; Grindrod SC; Dakshanamurthy S; Yang Y; Paige M; Brown ML
    Bioorg Med Chem; 2011 Apr; 19(8):2714-25. PubMed ID: 21440449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
    Cariou S; Donovan JC; Flanagan WM; Milic A; Bhattacharya N; Slingerland JM
    Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9042-6. PubMed ID: 10908655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
    Wesierska-Gadek J; Krystof V
    Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
    Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
    J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
    Brandi G; Paiardini M; Cervasi B; Fiorucci C; Filippone P; De Marco C; Zaffaroni N; Magnani M
    Cancer Res; 2003 Jul; 63(14):4028-36. PubMed ID: 12874002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in CDK inhibitors for cancer therapy.
    Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
    Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.